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Abstract
Background: Pulmonary Hypertension is a severe and incurable disease with poor prognosis. A
suite of new disease-specific measures – the Cambridge Pulmonary Hypertension Outcome Review
(CAMPHOR) – was recently developed for use in this condition. The purpose of this study was to
develop and validate a preference based measure from the CAMPHOR that could be used in cost-
utility analyses.
Methods: Items were selected that covered major issues covered by the CAMPHOR QoL scale
(activities, travelling, dependence and communication). These were used to create 36 health states
that were valued by 249 people representative of the UK adult population, using the time trade-off
(TTO) technique. Data from the TTO interviews were analysed using both aggregate and individual
level modelling. Finally, the original CAMPHOR validation data were used to validate the new
preference based model.
Results: The predicted health state values ranged from 0.962 to 0.136. The mean level model
selected for analyzing the data had good explanatory power (0.936), did not systematically over-
or underestimate the observed mean health state values and showed no evidence of auto
correlation in the prediction errors. The value of less than 1 reflects a background level of ill health
in state 1111, as judged by the respondents. Scores derived from the new measure had excellent
test-retest reliability (0.85) and construct validity. The CAMPHOR utility score appears better able
to distinguish between WHO functional classes (II and III) than the EQ-5D and SF-6D.
Conclusion: The tariff derived in this study can be used to classify an individual into a health state
based on their responses to the CAMPHOR. The results of this study widen the evidence base for
conducting economic evaluations of interventions designed to improve QoL for patients with PH.
Background
Pulmonary hypertension (PH) is a disease characterized
by a progressive rise in pulmonary artery pressure and pul-
monary vascular resistance, ultimately resulting in right
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heart failure and death [1]. Symptoms include breathless-
ness, fatigue, palpitations, ankle oedema, chest pain, and
syncope. Treatments for PH range from oral endothelin
receptor antagonists through to nebulised or continuous
intravenous or sub-cutaneous infusions of prostaglandin
or prostaglandin analogues [2]. Many of these treatments
are inconvenient or have significant adverse effects. For
example, intravenous Prostacyclin [3] is associated with
diarrhoea, systemic flushing, headaches, jaw pain and
hypotension. Current treatments for PH (with the excep-
tion of pulmonary endarterectomy for thromboembolic
PH) do not cure the disease.
The present aim of treatment is to lengthen survival time,
to ameliorate symptoms and to improve quality of life
(QoL). However, treatments for PH are expensive. For
example, Epoprostenol costs up to £71,000 per patient
per year in the UK [4]. Given this cost there is a need to
determine the benefits of such treatment.
Several countries have produced guidelines for the con-
duct of economic evaluations in health care including
Canada [5], Australia [6] and the UK [7]. All guidelines
indicate that the preferred methodology is cost utility
analysis (CUA) whereby the benefits of health care inter-
ventions are measured according to quality adjusted life
years (QALYs). In addition, there is general agreement
that where possible a generic preference based measure of
health status based on general population values should
be used to calculate QALYs. Generic preference based
measures of health status include the EQ-5D [8], the SF-
6D [9] and the HUI-3 [10]. However, for some specific
clinical conditions generic measures may be considered
inappropriate due to their lack of sensitivity and relevance
[11,12]. Pulmonary hypertension represents such a condi-
tion. In addition, there is evidence that disease-specific
utility measures are more responsive than generic ones
[13,14].
Until recently only generic health status measures were
available for assessing the impact of PH from the patients'
perspective. The Cambridge Pulmonary Hypertension
Outcome Review (CAMPHOR) was developed as a PH-
specific measure to fill this gap [15]. It consists of three
separate scales that are specific to PH; symptoms, func-
tioning and QoL. The content of the measure was derived
directly from PH patients and all scales have been shown
to have good face and content validity, reliability, repro-
ducibility and construct validity [15]. Furthermore, all
scales have been shown to fit the Rasch model indicating
that they represent unidimensional scales [15,16]. The
analysis also shows how severe each item is in relation to
the construct being measured. However, scores from such
a measure cannot be used directly to undertake economic
evaluations of treatments. First it is necessary to convert it
into a preference based measure. The approach used in
this paper has been developed in Sheffield and used in the
construction of the SF-6D and King's Health Question-
naire [9,17].
An advantage of converting a disease-specific measure is
that the resulting utility values calculated will be specific
to the condition in question. If the source measure was
carefully developed then all the items will be relevant to
the respondents' condition and no important issue will
have been omitted.
The purpose of the present paper is to describe the devel-
opment and validation of a preference based measure
from the CAMPHOR that would yield utility values for
patients with PH and allow more accurate economic eval-
uations of PH treatments.
Methods
Item selection
As the ultimate purpose of the study was to calculate
QALYs, it was decided to construct the preference based
measure from the 25-item CAMPHOR QoL scale. Fewer
items are included in a preference based measure as, oth-
erwise, it would require an unmanageable number of val-
uations in order to determine the utility of all possible
health states. Consequently, a simplified health state clas-
sification for CAMPHOR was developed based on a sam-
ple of six items. These six items were combined into four
domains such that two domains had three levels and the
other two domains had two levels. The items were selected
by re-analysis of the responses of 201 patients to the CAM-
PHOR QoL scale. The following criteria were employed
for item selection:
• Percentage affirmation of item: Items that were affirmed
by a very small or very large proportion of the sample were
excluded.
￿ Item severity as assessed by logit location in Rasch anal-
ysis: Items with extreme logit locations (derived from the
Rasch analyses) were candidates for exclusion. However,
it was the aim to include a reasonable spread of items in
terms of the degree of severity they represented. The logit
severity of the selected items ranged from -1.25 to 2.09.
￿ Regression: Ordinal regression was employed using
CAMPHOR QoL responses to predict a general health per-
ception variable (response options 'Very good', 'Good',
'Fair', and 'Poor'). Items that significantly predicted this
variable were candidates for inclusion in the utility exer-
cise.Health and Quality of Life Outcomes 2008, 6:65 http://www.hqlo.com/content/6/1/65
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￿ Content of item: In addition to the statistical methods
listed above it was important to select items that covered
a range of issues included in the CAMPHOR scale.
Valuation survey
The main valuation survey was undertaken using the time
trade-off (TTO) technique where individuals are asked to
undertake conventional TTO valuations for a sample of
health states. The Measurement and Valuation of Health
(MVH) group version of TTO [18] was used to allow com-
parison with the EQ-5D tariff.
A representative sample of the adult general population
was invited to participate in the study. Consenting adults
were visited in their home for the TTO interview. A small
pilot study (n = 15) was undertaken in advance of the
main study to check that interviewees understood the task
and were answering the questions as expected. The final
sample size for this study was 249 individuals.
At the start of each interview respondents were given a
self-completed questionnaire containing the EQ-5D and
the CAMPHOR health state classification to complete.
Respondents were then asked to rank the CAMPHOR
health states from best to worst in order to help familiar-
ize them with the states. The main elicitation task
involved the use of a visual prop designed by the MVH
group for use in the UK valuation of the EQ-5D. For
health states that a respondent regards as better than being
dead, they are asked to imagine two scenarios: 1) live in a
state for 10 years (t) and 2) a shorter period (x) in perfect
health. The time in the shorter state is varied until
respondents are unable to choose between these two sce-
narios, at which point the value of the state is given as x/t.
For states respondents regard as worse than being dead,
the choice is between 1) dying immediately and 2) spend-
ing a period of time (x) in the state followed by (10-x)
years in perfect health. Respondents were initially taken
through a hypothetical TTO exercise to help them under-
stand the task. They were then asked to undertake a total
of nine TTO tasks. Finally, the interview concluded with a
series of socio-demographic questions.
For states better than being dead, the value of the health
state x/t is bounded by 1.0 for perfect health and zero for
states as bad as being dead. For states worse than being
dead, health state values were calculated using the for-
mula -(10-x)/10 to ensure it is bounded by -1.0 [19].
Modeling health state values
The data from the TTO interviews were analysed using two
approaches based on aggregate and individual level mod-
elling. First, ordinary least squares (OLS) were used to esti-
mate a mean level model. The mean health state values
were the dependent variable and the independent varia-
bles were a series of dummy explanatory variables repre-
senting each level of the CAMPHOR dimensions. The
mean level model is defined as:
Yi = f(β'xij) + i (1)
Where the dependent variable Yi is the mean TTO value
for each health state and x is a vector of dummy explana-
tory variables (x∂λ) for each level λ of dimension ∂ of the
simplified CAMPHOR classification. For example, x31
denotes dimension ∂ = 3 (dependence), level λ = 1 (I don't
feel very dependent). For any given health state x∂λ will be
defined as follows:
x∂λ = 1, if for this state dimension ∂ is at level λ
x∂λ = 0, if for this state, dimension ∂ is not at level λ
There are six of these terms in total with level λ = 1 acting
as a baseline for each dimension. Hence for a simple lin-
ear model, the intercept (or constant) represents state
1111 and summing the coefficients of the 'on' dummies
derives the value for all other states. i is the error term
which is assumed to be independent with constant vari-
ance structure.
Secondly, a random effects model was used based on indi-
vidual observations. This model specification takes
account of the repeated measurement aspect of the data
where multiple responses are obtained from the same
individual.
The random effects model is defined as:
Yij = f(β'xij) + ij (2)
Where i = 1,2...n represent individual health state values
and j = 1,2...m represents respondents. The dependent
variable Yij is the value assigned to each health state (i)
valued by respondent j, x is a vector of dummy explana-
tory variables (x∂λ) defined as previously and ij is the error
term which is subdivided as follows:
ij = uj + eij (3)
Where uj is respondent specific variation and eij is an error
term for the ith health state valuation of the jth individual.
This is assumed to be random across observations.
Validation of the CAMPHOR preference based measure
After the valuation exercise it was possible to use the
resulting weights for the six items to calculate utility data
for previously collected CAMPHOR responses. Data col-
lected in a previous study [15] were available to validate
the new preference based measure (which is embedded inHealth and Quality of Life Outcomes 2008, 6:65 http://www.hqlo.com/content/6/1/65
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the CAMPHOR QoL scale). This study involved adminis-
tering the CAMPHOR to 91 PH patients on two occasions,
two weeks apart. In addition, the EQ-5D was adminis-
tered on the second occasion. The following psychometric
properties of the new measure were assessed; test-retest
reliability (reproducibility) and construct validity (utility
scores compared between perceived general health groups
and between PH severity groups based on CAMPHOR
symptom scores).
Ethical approval was sought and gained for the validation
survey.
Results
Table 1 includes details of items selected. The internal
consistency for these six items was 0.72.
Derivation of health state classification
Four domains were captured using the six selected CAM-
PHOR items; social activities, travelling, dependence and
communication. Two items each provided three levels for
the social activities (I can join in activities with family and
friends, I'm unable to join in activities with family and
friends, I feel very isolated) and Travelling (Travelling dis-
tances is not a problem, Travelling distances is a problem,
I am reluctant to leave the house) domains. One item
each provided two levels for the Dependence (I don't feel
very dependent and I feel very dependent) and Commu-
nication (I never find speaking too much of an effort and
Sometimes it's too much effort to speak) domains. A full
factorial design produced 36 health states for valuation.
The health states were stratified into mild, moderate and
severe classifications. A sample of health states defined by
the CAMPHOR items can be seen in Table 2. The health
states were chosen to reflect a range of possible health
states defined by the classification rather than predomi-
nantly a 'good' or 'bad' selection of health states.
Valuation survey
Descriptive characteristics of the respondents included in
the valuation survey are included in Table 3. It can be seen
that a majority of respondents were female, married and
had experience of serious illness in their own families.
Over 60% of respondents had education beyond the min-
imum school leaving age with over 40% holding a degree
or equivalent professional qualification.
The health state values ranged from 0.770 to 0.156 and
generally had fairly large standard deviations (ranging
from 0.250 to 0.532).
Table 4 shows the results for the mean level and random
effects main effects only models (models 1 and 2).
For the mean level model, all of the coefficients had the
expected negative sign and were statistically significant (p
< 0.01). The coefficient estimates also increased with
absolute size as the level of each dimension worsened.
The explanatory power of the mean level model was 0.936
which is very high indicating that the model is a good fit
for the data. For the random effects model, the results
were similar in that all the coefficients had the expected
negative sign but differed from the mean level model as
not all of the coefficients increased with absolute size as
the level of each dimension worsened (namely the move-
ment from level 2 to level 3 in social activities and the
movement from level 2 to level 3 in travelling). In com-
mon with the mean level model, all of the coefficients
were statistically significant (p < 0.01). The explanatory
power of the random effects model (0.373) was, however,
somewhat lower than that of the mean level model which
was not surprising given the much larger number of actual
data points which this model is aiming to fit. The predic-
tive ability of the two models was quite similar with both
models resulting in a similar proportion of errors greater
than 0.05 (35% for the mean level model and 38% for the
random effects models, respectively) and both models
resulting in two predictive errors greater than 0.10.
In both mean and random effects models the predictions
were unbiased (t-test) indicating that neither model sys-
tematically over or under estimated the observed mean
value and the Ljung-Box (LB) statistics suggested that
there was no evidence of auto-correlation in the predic-
tion errors of both models, when the errors are ordered by
actual mean health state valuation.
Table 1: Item selection details
Item %
 affirmation
Corrected
item-total
  correlation
Factor
 loading
Rasch
 location
Mean
 change
7 32.2 .49 .54 0.84 0.07
12 65.9 .54 .60 -1.25 0.07
13 14.4 .30 .33 2.09 0.16
15 38.9 .64 .69 0.42 0.10
24 19.3 .46 .50 1.88 0.09
25 60.9 .64 .69 -1.00 0.00Health and Quality of Life Outcomes 2008, 6:65 http://www.hqlo.com/content/6/1/65
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As the upper anchor for the analyses was perfect health
and not the best state as defined by the CAMPHOR utility
scale, the predicted utility value for the latter was less than
1. This was necessary since, for the purpose of calculating
QALYs, results must lie on a scale where '1' is full health
and '0' represents death. The predicted values of state
1111 is the constant term, which had values of 0.962 and
0.961 in the mean and RE models, respectively.
Table 5 presents examples comparing the predicted values
according to each model and the actual values for each
health state.
Validation of the preference based CAMPHOR scale
A majority (87.8%) of the 91 participants in the CAM-
PHOR validation survey were in New York Heart Associa-
tion (NYHA) classes II and III. The correlation between
the CAMPHOR QoL scores and the CAMPHOR preference
based scores was 0.86.
Test-retest reliability
After removal of cases where there were 7 days < or >21
days between administrations or where perceived health
changed between administrations, the test-retest coeffi-
cient was 0.85. Tables 6 and 7 show how the preference
weights are related to perceived general health and PH
severity, respectively. In both cases Kruskal-Wallis tests
Table 2: Sample health states defined by CAMPHOR
I can join in activities with my family and friends
Travelling distances is not a problem
I feel very dependent
I never find speaking too much of an effort
I can join in activities with my family and friends
Travelling distances is not a problem
I feel very dependent
Sometimes it's too much effort to speak
I can join in activities with my family and friends
Travelling distances is a problem
I don't feel very dependent
I never find speaking too much of an effort
Table 3: Descriptive characteristics of respondents
Characteristics Respondents
N%
Age
18–25 12 4.8
26 to 35 28 11.2
36 to 45 63 25.3
46 to 55 54 21.7
56 to 65 50 21.1
66+ 42 16.9
Gender
Male 96 38.6
Female 153 61.4
Relationship status
Married/living with partner 192 77.1
Living alone 57 22.9
Personal experience of serious illness
Yes 81 32.5
No 168 67.5
Experience of serious illness in family
Yes 164 66.1
No 84 33.9
Experience of serious illness in caring for others
Yes 119 48.0
No 129 52.0
Main activity
Employed or self employed 140 56.2
Other 109 43.8
Education after minimum school leaving age
Yes 151 60.6
No 98 39.4
Degree or equivalent professional qualification
Yes 103 41.4
No 146 58.6Health and Quality of Life Outcomes 2008, 6:65 http://www.hqlo.com/content/6/1/65
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showed that the differences in utility were statistically sig-
nificant (p < .001).
Similar values were found for the mean preference
weights obtained for the CAMPHOR and EQ-5D in NYHA
Class II (Table 8). These values are also relatively similar
to those found in a PH study that obtained utility values
from the SF-6D [20]. However, there were marked differ-
ences between these three measures for Class III patients
with the CAMPHOR utility scores being substantially
lower than those on the EQ-5D and SF-6D. The CAM-
PHOR-generated preference weights showed greater sensi-
tivity in terms of differentiating between NYHA classes. To
illustrate this; if patients were to improve from NYHA
Class III to Class II the effect size (difference in mean score
divided by standard deviation at baseline) would be 0.71–
0.92 for the CAMPHOR measure – a large effect size –
compared with 0.42 for the EQ-5D. A moderately sized
correlation (0.60) was found between the values derived
from the two measures.
Discussion
The results from this study present a method for analysing
existing and future data from clinical trials and other evi-
dence sources where the CAMPHOR has been employed.
Thus the CAMPHOR is now able to provide data on
health state values in addition to PH-specific symptoma-
tology, functioning and QoL. The methodology employed
has produced preference data that can be applied within
the framework of cost utility analysis in economic evalua-
tion.
The mean level (model 1) is broadly consistent with a pri-
ori expectations in terms of coefficient size and direction
of preference in relation to worsening levels of each
dimension. The predicted health state values from this
model also broadly conform to the logical ordering of the
simplified CAMPHOR classification. This is not the case
for the random effects model (model 2) which fails to
indicate the direction of preference expected in terms of
worsening levels of the social and travelling dimensions.
Hence, it is recommended that Model 1 (the aggregate
mean level model) be used. This model is superior
because it removes inconsistencies and because of its high
performance in terms of explanatory power and predictive
Table 4: Consistent Mean and Random effects model results
Mean level – model 1 Random effects – model 2
Disvalue Coef. (95% CI) P
value
Coef. (95% CI) P
value
Lev2 social act. -0.297 (-0.345 to -0.249) <0.001 -0.307 (-0.337 to -0.276) <0.001
Lev3 social act. -0.308 (-0.357 to -0.258) <0.001 -0.304 (-0.334 to -0.274) <0.001
Lev2 travelling -0.202 (-0.250 to -0.154) <0.001 -0.207 (-0.240 to -0.174) <0.001
Lev3 travelling -0.223 (-0.273 to -0.173) <0.001 -0.205 (-0.235 to -0.175) <0.001
Lev2 dependence -0.147 (-0.188 to -0.108) <0.001 -0.156 (-0.181 to -0.131) <0.001
Lev2 speaking -0.147 (-0.187 to -0.107) <0.001 -0.141 (-0.166 to -0.116) <0.001
Constant 0.962 (0.905 to 1.020) <0.001 0.961 (0.907 to 1.015) <0.001
N 34 249
Adjusted R2 0.936 0.373
Inconsistencies 0 2
Mean absolute error 0.041 0.042
No. > 0.05 12 (35%) 13(38%)
No. > 0.10 2 (6%) 2 (6%)
Mean error 0.000 0.004
LB 8.582 10.711
Table 5: Comparison of predicted and actual values for selected 
health state classifications: mean level (ML) and random effects 
(RE) models
Health
 State
Actual mean Estimated mean
 (ML) model
Estimated mean
 (RE) model
1111 N/A 0.962 0.961
1211 0.770 0.760 0.754
2121 0.515 0.517 0.498
2312 0.272 0.295 0.308
3322 0.156 0.136 0.155
Table 6: Association between preference weights and perceived 
general health
Rating of general health N Utility
Very good/good 35 0.69
Fair 36 0.49
Poor 16 0.37Health and Quality of Life Outcomes 2008, 6:65 http://www.hqlo.com/content/6/1/65
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ability. The tariff can be applied by classifying individuals
into particular health states on the basis of their responses
to the CAMPHOR. For example, an individual who indi-
cates that they can join in activities with family and
friends, that travelling distances is a problem, that they
feel very dependent, and sometimes find it too much of an
effort to speak, would be classified in health state 1222.
The corresponding value for that health state according to
the recommended model is 0.465. All other health state
classifications arising from the CAMPHOR can be valued
using the same approach.
The CAMPHOR preference-based measure exhibited high
correlations with the CAMPHOR QoL scale. High test-
retest values indicate that the new utility scale has excel-
lent reproducibility while evidence of the scale's validity
was found in its ability to discriminate effectively between
patients who have differing levels of disease severity.
The estimation of preference weights for disease-specific
QoL instruments is relatively rare and some health econ-
omists have expressed scepticism about the value of such
an exercise [21]. However, the main argument for using
disease-specific descriptive systems rests on the premise
that they are far more likely to be sensitive to changes in
the condition under consideration (supported by results
from the present validation exercise) and are more rele-
vant to the concerns of patients than generic measures
[22,23]. The effect size results show that the disease-spe-
cific measure is better able to distinguish signal from
noise than the generic measures. This has important
implications for sample sizes in trials. While it is accepted
that for use in economic evaluation it is the absolute dif-
ference and not the effect size that determines cost effec-
tiveness, the standard deviation influences the degree of
uncertainty in the probabilistic sensitivity analysis [24].
There may also be a concern that the values produced by
a disease-specific measure will not be comparable to those
produced by a generic measure. However, it can be con-
tended that providing the descriptive system is valued on
the same scale using the same variant of the same valua-
tion technique, as was the case for the CAMPHOR and
EQ-5D models, then the valuations should be compara-
ble [25].
The valuation exercise found that the best state defined by
the CAMPHOR items was below 1. It is clear from this and
other studies that individuals valuing the best health state
(i.e. that with no health problems) are still judged to have
impaired health status as reflected by a mean utility value
lower than 1 [26,27]. It is interesting to note that in the
development of the EQ-5D the state of perfect health was
not valued and was assumed to be 1 [19]. This anchoring
meant that in the PH validation sample around 8% of
patients had perfect health according to the EQ-5D. It is
questionable whether any individuals with PH would
consider themselves to have perfect health given the
severe nature of the symptoms, the fact that the condition
is often not diagnosed until late in its progression and the
poor prognosis. Given these factors, it is possible that the
CAMPHOR utility scale provides a more realistic estimate
of utility in PH.
Conclusion
This research has demonstrated that it is possible to esti-
mate preference weights for a disease-specific measure
relating to pulmonary hypertension. The results can be
applied to any data set including the CAMPHOR and
hence widen the evidence base for conducting economic
evaluations of new pharmaceuticals and other health care
interventions designed to improve QoL for patients living
with this serious condition.
The CAMPHOR preference-based measure has been
shown to have very good psychometric properties. It has
Table 7: Association between preference weights and perceived 
severity of PH
PH symptom severity N Utility
Mild 18 0.90
Moderate 23 0.56
Quite severe 22 0.49
Very severe 23 0.31
Table 8: Preference weights for NYHA Classes II and III
Mean (SD) utility value CAMPHOR EQ-5D SF-6D
Time 1 Time 2
NYHA Class II 0.70 (0.24) 0.66 (0.29) 0.69 (0.24) 0.67 (0.10)
NYHA Class III 0.48 (0.24) 0.45 (0.24) 0.59 (0.24) 0.60 (0.10)
Difference 0.22 0.20 0.10 0.07
Effect size if patients move from Class III to Class II 0.92 0.71 0.42 0.70Publish with BioMed Central    and   every 
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excellent reproducibility, good construct validity and
superior sensitivity to the EQ-5D in this population.
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